Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 11/20 | 1.00 |
| ▸ | MAPT | P10636 | 5/20 | 1.00 |
| ▸ | TP53 | P04637 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.84 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.84 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.84 |
| ▸ | MEN1 | O00255 | 5/20 | 0.82 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.82 |
| ▸ | GBA1 | P04062 | 1/20 | 0.82 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.78 |
| ▸ | HTT | P42858 | 1/20 | 0.78 |
| ▸ | PDE5A | O76074 | 2/20 | 0.77 |
| ▸ | GAA | P10253 | 1/20 | 0.74 |
| ▸ | KDM1A | O60341 | 1/20 | 0.72 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.72 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.71 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.71 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22201364 | 0.97 | ABCG2 (0.94) | ABCG2MAPTTP53LMNAKDM4E | |
| SCHEMBL5531993 | 0.94 | ABCG2 (0.89) | ABCG2MAPTTP53LMNAKDM4E | |
| SCHEMBL1083796 | 0.92 | KDM4E (1.00) | ABCG2MAPTTP53LMNAKDM4E | |
| SCHEMBL8093527 | 0.90 | ABCG2 (0.82) | ABCG2MAPTTP53LMNAKDM4E | |
| SCHEMBL1063103 | 0.89 | ABCG2 (1.00) | ABCG2MAPTTP53LMNAKDM4E | |
| SCHEMBL5527457 | 0.88 | ABCG2 (0.83) | ABCG2MAPTTP53LMNAKDM4E | |
| SCHEMBL8087337 | 0.88 | ABCG2 (0.85) | ABCG2MAPTTP53LMNAKDM4E | |
| SCHEMBL4868573 | 0.88 | ABCG2 (1.00) | ABCG2MAPTTP53LMNAKDM4E | |
| SCHEMBL8096436 | 0.87 | ABCG2 (0.76) | ABCG2MAPTTP53LMNAKDM4E | |
| SCHEMBL14262835 | 0.86 | ABCG2 (0.82) | ABCG2MAPTTP53LMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120009142-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2012-01-12 | — | — | US | disclosed |
| US-7973069-B2 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. (US) | 2011-07-05 | — | — | US | disclosed |
| US-20100305100-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| US-20100292187-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2010-11-18 | — | — | US | disclosed |
| WO-2009000085-A1 | QUINOLINE AND QUINAZOLINE DERIVATIVES USEFUL AS MODULATORS OF GATED ION CHANNELS | PAINCEPTOR PHARMA CORPORATION (CA) | 2008-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120009142-A1 | METHODS FOR TREATING HEPATITIS C | OAT, HAVCR2, HCCS | ABCG2 3831/4885MAPT 4416/4885TP53 3022/4885 |
| US-20100292187-A1 | METHODS FOR TREATING HEPATITIS C | HAVCR2, EIF2AK2, MAVS | ABCG2 3868/4885MAPT 4477/4885TP53 1262/4885 |
| US-20100305100-A1 | METHODS FOR TREATING HEPATITIS C | HAVCR2, EIF2AK2, MAVS | ABCG2 3868/4885MAPT 4477/4885TP53 1262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.